Table 2.
TSQM-II Summary Scores
| Treatment | Patients | Physicians | P | |
|---|---|---|---|---|
| All medications (patients’ questionnaire)/csDMARDs (physicians’ questionnaire)a | N | 1237 | 146 | |
| Effectiveness | Median (range) | 83.3 (0–100) | 66.7 (33.3–100) | |
| Side effects | Median (range) | 100 (16.7–100) | 75 (16.7–100) | |
| Convenience | Median (range) | 81.3 (18.6–100) | 68.8 (31.3–100) | |
| Global satisfaction | Median (range) | 83.3 (8.3–100) | 66.7 (16.7–100) | |
| bDMARDsa | N | 335 | 146 | |
| Effectiveness | Median (range) | 83.3 (0–100) | 75 (33.3–100)* | 0.302 |
| Side effects | Median (range) | 100 (8.3–100) | 87.5 (16.7–100)* | <0.001 |
| Convenience | Median (range) | 75 (0–100) | 68.8 (12.5–100) | 0.001 |
| Global satisfaction | Median (range) | 75 (0–100) | 75 (16.7–100)* | 0.889 |
Notes: aSatisfaction with all medications or bDMARDs was assessed in the patients’ questionnaire, while satisfaction with csDMARDs or bDMARDs was assessed in the physicians’ questionnaire. *P<0.05, bDMARDs vs csDMARDs in physicians.
Abbreviations: bDMARDs, biological disease-modifying antirheumatic drugs; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; SD, standard deviation.